Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 1;65(8):1286-1292.
doi: 10.2967/jnumed.123.267256.

Performing [18F]MFBG Long-Axial-Field-of-View PET/CT Without Sedation or General Anesthesia for Imaging of Children with Neuroblastoma

Affiliations

Performing [18F]MFBG Long-Axial-Field-of-View PET/CT Without Sedation or General Anesthesia for Imaging of Children with Neuroblastoma

Lise Borgwardt et al. J Nucl Med. .

Abstract

Meta-[123I]iodobenzylguanidine ([123I]MIBG) scintigraphy with SPECT/CT is the standard of care for diagnosing and monitoring neuroblastoma. Replacing [123I]MIBG with the new PET tracer meta-[18F]fluorobenzylguanidine ([18F]MFBG) and further improving sensitivity and reducing noise in a new long-axial-field-of-view (LAFOV) PET/CT scanner enable increased image quality and a faster acquisition time, allowing examinations to be performed without sedation or general anesthesia (GA). Focusing on feasibility, we present our first experience with [18F]MFBG LAFOV PET/CT and compare it with [123I]MIBG scintigraphy plus SPECT/CT for imaging in neuroblastoma in children. Methods: A pilot of our prospective, single-center study recruited children with neuroblastoma who were referred for [123I]MIBG scintigraphy with SPECT/CT. Within 1 wk of [123I]MIBG scintigraphy and SPECT/low-dose CT, [18F]MFBG LAFOV PET/ultra-low-dose CT was performed 1 h after injection (1.5-3 MBq/kg) without sedation or GA, in contrast to the 24-h postinjection interval needed for scanning with [123I]MIBG, the 2- to 2.5-h acquisition time, and the GA often needed in children less than 6 y old. Based on the spirocyclic iodonium-ylide precursor, [18F]MFBG was produced in a fully automated good manufacturing practice-compliant procedure. We present the feasibility of the study. Results: In the first paired scans of the first 10 children included (5 at diagnosis, 2 during treatment, 2 during surveillance, and 1 at relapse), [18F]MFBG PET/CT scan showed a higher number of radiotracer-avid lesions in 80% of the cases and an equal number of lesions in 20% of the cases. The SIOPEN score was higher in 50% of the cases, and the Curie score was higher in 70% of the cases. In particular, intraspinal, retroperitoneal lymph node, and bone marrow involvement was diagnosed with much higher precision. None of the children (median age, 1.6 y; range, 0.1-7.9 y) had sedation or GA during the PET procedure, whereas 80% had GA during [123I]MIBG scintigraphy with SPECT/CT. A PET acquisition time of only 2 min without motion artifacts was the data requirement of the 10-min acquisition time for reconstruction to provide a clinically useful image. Conclusion: This pilot study demonstrates the feasibility of performing [18F]MFBG LAFOV PET/CT for imaging of neuroblastoma. Further, an increased number of radiotracer-avid lesions, an increased SIOPEN score, and an increased Curie score were seen on [18F]MFBG LAFOV PET/CT compared with [123I]MIBG scintigraphy with SPECT/CT, and GA and sedation was avoided in all patients. Thus, with a 1-d protocol, a significantly shorter scan time, a higher sensitivity, and the avoidance of GA and sedation, [18F]MFBG LAFOV PET/CT shows promise for future staging and response assessment and may also have a clinical impact on therapeutic decision-making for children with neuroblastoma.

Keywords: [18F]MFBG; [18F]MFBG LAFOV PET/CT; neuroblastoma; pediatrics; total-body PET/CT.

PubMed Disclaimer

Figures

None
Graphical abstract
FIGURE 1.
FIGURE 1.
PET images obtained in list mode in 30-s increments, excluding periods of motion artifacts in reconstruction of images.
FIGURE 2.
FIGURE 2.
Sagittal and axial view of tracer uptake in pineal gland (arrows, A) and pituitary gland (arrows, B) seen on [18F]MFBG LAFOV PET/MRI. A = anterior; P = posterior.
FIGURE 3.
FIGURE 3.
(A) [18F]MFBG LAFOV PET/ULD CT (top) and [123I]MIBG scintigraphy with SPECT/LD CT images (bottom) of 7-wk-old girl with neuroblastoma. [18F]MFBG image shows intraspinal and bone marrow involvement not seen on [123I]MIBG image. [18F]MFBG PET/ULD CT image shows uptake in tumor in right hemithorax with intraspinal involvement with direct extension into neural foramina and spinal canal between thoracic vertebrae 4/5 and 5/6 (top red arrow), several liver lesions (middle red arrow), and in bone marrow of right tibia (bottom red arrow). [123I]MIBG scintigraphy with SPECT/LD CT image shows only large thoracic tumor (top purple arrow) and liver metastases (bottom purple arrow). Spinal involvement and bone marrow involvement could not be identified on [123I]MIBG scintigraphy with SPECT/LD CT. (B) [18F]MFBG LAFOV PET/ULD CT and [123I]MIBG scintigraphy with SPECT/LD CT images of 6-y-old girl with paravertebral relapse of neuroblastoma stage IV in left adrenal gland without N-Myc gene amplification. [18F]MFBG image shows lymph node involvement not seen on [123I]MIBG image. [18F]MFBG PET/ULD CT postoperative image, after resection of paravertebral relapse, shows uptake in left-side cervical lymph node (top left red arrows) and 2 retroperitoneal lymph nodes (top right red arrows), not identified on [123I]MIBG scintigraphy with SPECT/LD CT. A = anterior; MIP = maximum-intensity projection.

References

    1. Monclair T, Brodeur GM, Ambros PF, et al. . The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;10:298–303. - PMC - PubMed
    1. Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer. 2011;56:578–583. - PubMed
    1. Bar-Sever Z, Biassoni L, Shulkin B, et al. . Guidelines on nuclear medicine imaging in neuroblastoma. Eur J Nucl Med Mol Imaging. 2018;45:2009–2024. - PubMed
    1. Piccardo A, Treglia G, Fiz F, et al. . The evidence-based role of catecholaminergic PET tracers in neuroblastoma: a systematic review and a head-to-head comparison with mIBG scintigraphy. Eur J Nucl Med Mol Imaging. 2024;51:756–767. - PMC - PubMed
    1. Pandit-Taskar N, Zanzonico P, Staton KD, et al. . Biodistribution and dosimetry of 18F-meta-fluorobenzylguanidine: a first-in-human PET/CT imaging study of patients with neuroendocrine malignancies. J Nucl Med. 2018;59:147–153. - PMC - PubMed

LinkOut - more resources